Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast in Behçet's Disease
NCT00866359Phase 2Completed
- Sponsor
- Amgen
- Start
- Aug 2009
- Primary completion
- May 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in Behçet's disease (BD) comparing Apremilast with Placebo (2 arms). Primary endpoint: Number of Oral Ulcers at Day 85. Started Aug 2009; status: completed.
02
Drugs
apremilast
03
Conditions
Behçet's disease (BD)
Beyond the preview
Go deeper on NCT00866359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00866359.